DK3689871T3 - 4,6,7-trisubtitueret 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivat og anvendelse - Google Patents

4,6,7-trisubtitueret 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivat og anvendelse Download PDF

Info

Publication number
DK3689871T3
DK3689871T3 DK18862262.5T DK18862262T DK3689871T3 DK 3689871 T3 DK3689871 T3 DK 3689871T3 DK 18862262 T DK18862262 T DK 18862262T DK 3689871 T3 DK3689871 T3 DK 3689871T3
Authority
DK
Denmark
Prior art keywords
trisubtituated
dihydropyrrol
pyrimidin
pyridin
derivatives
Prior art date
Application number
DK18862262.5T
Other languages
English (en)
Inventor
Shuchun Guo
Fusheng Zhou
Xiang Chen
Jinzhu Zhao
Dong Huang
Jing Xie
Changjiang Qiao
Wan He
Kai Zhang
Xi Chen
Jiong Lan
Original Assignee
Shanghai Haiyan Pharmaceutical Tech Co Ltd
Yangtze River Pharm Group Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Haiyan Pharmaceutical Tech Co Ltd, Yangtze River Pharm Group Co filed Critical Shanghai Haiyan Pharmaceutical Tech Co Ltd
Application granted granted Critical
Publication of DK3689871T3 publication Critical patent/DK3689871T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK18862262.5T 2017-09-28 2018-08-03 4,6,7-trisubtitueret 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivat og anvendelse DK3689871T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710897909 2017-09-28
PCT/CN2018/098481 WO2019062329A1 (zh) 2017-09-28 2018-08-03 4,6,7-三取代1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途

Publications (1)

Publication Number Publication Date
DK3689871T3 true DK3689871T3 (da) 2021-12-06

Family

ID=65900477

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18862262.5T DK3689871T3 (da) 2017-09-28 2018-08-03 4,6,7-trisubtitueret 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivat og anvendelse

Country Status (9)

Country Link
US (2) US11174254B2 (da)
EP (1) EP3689871B1 (da)
JP (1) JP6922085B2 (da)
CN (3) CN110267954B (da)
AU (1) AU2018342342B2 (da)
CA (1) CA3077238C (da)
DK (1) DK3689871T3 (da)
SG (1) SG11202002767RA (da)
WO (2) WO2019062329A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
CA3079292A1 (en) * 2017-10-19 2019-04-25 Bayer Animal Health Gmbh Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CN112334469B (zh) * 2019-03-18 2022-10-04 上海海雁医药科技有限公司 Btk抑制剂及其药学上可接受的盐和多晶型物及其应用
WO2022048551A1 (zh) * 2020-09-01 2022-03-10 上海海雁医药科技有限公司 布鲁顿酪氨酸激酶抑制剂的多晶型物及其制备方法和应用
WO2022121900A1 (zh) * 2020-12-07 2022-06-16 南京明德新药研发有限公司 吡咯并吡啶类化合物及其应用
CN113061137B (zh) * 2021-04-02 2022-08-02 广西医科大学 含氮杂环衍生物或其药学上可接受的盐和用途
WO2025022299A1 (en) * 2023-07-21 2025-01-30 Glenmark Pharmaceuticals Ltd Substituted pyrimidine compounds as irak-m degraders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3235B1 (ar) * 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
DK2516434T3 (da) * 2009-12-23 2015-08-31 Takeda Pharmaceutical Fusionerede heteroaromatiske pyrrolidinoner som syk-inhibitorer
WO2012177714A1 (en) * 2011-06-22 2012-12-27 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
RS60934B1 (sr) * 2013-09-30 2020-11-30 Guangzhou Innocare Pharma Tech Co Ltd Supstituisani nikotinimidni inhibitori btk i njihova priprema i upotreba u lečenju karcinoma, inflamatorne i autoimune bolesti
KR20160063366A (ko) * 2013-10-21 2016-06-03 메르크 파텐트 게엠베하 Btk 저해제로서 헤테로아릴 화합물 및 이들의 용도
EP4019518A1 (en) * 2014-02-28 2022-06-29 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2015158310A1 (zh) * 2014-04-18 2015-10-22 山东轩竹医药科技有限公司 一种酪氨酸激酶抑制剂及其用途
WO2016000615A1 (en) * 2014-07-02 2016-01-07 Sunshine Lake Pharma Co., Ltd. Heteroaryl compounds and pharmaceutical applications thereof
FI3236943T3 (fi) * 2014-12-24 2023-04-27 Principia Biopharma Inc Koostumuksia ileo-jejunaaliseen lääkkeenantoon
WO2017075394A1 (en) 2015-10-29 2017-05-04 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2
CN107021963A (zh) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用

Also Published As

Publication number Publication date
EP3689871B1 (en) 2021-09-29
CA3077238A1 (en) 2019-04-04
WO2019062328A1 (zh) 2019-04-04
CN110366553A (zh) 2019-10-22
WO2019062329A1 (zh) 2019-04-04
CA3077238C (en) 2022-04-12
US11155546B2 (en) 2021-10-26
US11174254B2 (en) 2021-11-16
AU2018342342A1 (en) 2020-04-16
CN110267954B (zh) 2022-05-10
JP2020535170A (ja) 2020-12-03
EP3689871A4 (en) 2020-08-05
AU2018342342B2 (en) 2021-01-07
SG11202002767RA (en) 2020-04-29
US20200048248A1 (en) 2020-02-13
CN110267954A (zh) 2019-09-20
EP3689871A1 (en) 2020-08-05
CN110366553B (zh) 2022-04-15
JP6922085B2 (ja) 2021-08-18
US20200223846A1 (en) 2020-07-16
CN114478544B (zh) 2023-06-16
CN114478544A (zh) 2022-05-13

Similar Documents

Publication Publication Date Title
DK3846904T3 (da) 5-morpholin-4-yl-pyrazolo[4,3-b]pyridinderivater
ZA201904737B (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
SG11201912267SA (en) Nicotinamide riboside derivatives and their uses
DK3481827T3 (da) Imidazo[1,2-a]pyridinderivater, fremgangsmåder til fremstilling og anvendelse deraf
DK3297637T3 (da) Benzen-1,3,5-tricarboxamidderivater og anvendelser deraf
DK3359541T3 (da) N-sulfonylerede pyrazol[3,4-b]pyridin-6-carboxamider og fremgangsmåde til anvendelse
ZA201706040B (en) Maytansinoid derivatives, conjugates thereof, and methods of use
PL3181560T3 (pl) Pochodna pirydynoamidopirymidyny, sposób jej otrzymywania i zastosowanie
DK3371185T3 (da) 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus-kinase-inhibitorer
DK3712152T3 (da) 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer
IL263172A (en) The history of three-ring heterocycles, their preparation and use
IL261643B (en) Piperidine derivatives, their preparation and use
ZA201606794B (en) 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one derivatives and their use as antibacterial agents
EP3689871A4 (en) 1,2-DIHYDROPYRROL [3,4-C] PYRIDIN / PYRIMIDIN-3-ONE DERIVATIVE 4,6,7-TRISUBSTITUDE AND ITS USE
HUE067992T2 (hu) Aminopiridin származékok és szelektív ALK-2 gátlókként való alkalmazásuk
DK3604303T3 (da) Hidtil ukendt pyrrolopyridinderivat, fremgangsmåde til fremstilling heraf og anvendelse deraf
IL274722A (en) History of pyridinones and their use as selective inhibitors of ALK-2
HUE057202T2 (hu) Kombinációs kezelések 1H-pirazolo[4,3-b]piridinek alkalmazásával
DK3720855T3 (da) Imidazopyridinderivater og avendelsen deraf som medikament
IL262597B (en) Piperidinyl derivatives, their preparation and use
HUE038944T2 (hu) Tiokromeno[2,3-c]kinolin-12-on származékok és topoizomeráz inhibitorként való alkalmazásuk
HK40029730A (en) Pyridinone derivatives and their use as selective alk-2 inhibitors
HK40007022A (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
IL235077A0 (en) New derivatives of thiochromano[2,3-c]quino lin-12-one, its preparation method and application
SG10201406318YA (en) Novel thiochromeno[2,3-c]quinolin-12-one derivatives, preparation method and application thereof